{"id":"buprenorphine-chc","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Withdrawal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors, producing a ceiling effect on respiratory depression that makes it safer than full opioid agonists. The CHC (contingency-based counseling or contingency management component) reinforces abstinence and treatment adherence through behavioral incentives, enhancing the pharmacological efficacy of buprenorphine in opioid use disorder treatment.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist combined with a contingency management component (CHC) to treat opioid use disorder through both pharmacological and behavioral intervention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:25.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT00574067","phase":"PHASE3","title":"Buprenorphine for Prisoners","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2008-09","conditions":"Heroin Addiction","enrollment":213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"phase_3","status":"active","brandName":"Buprenorphine +CHC","genericName":"Buprenorphine +CHC","companyName":"Friends Research Institute, Inc.","companyId":"friends-research-institute-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine +CHC is a treatment for heroin addiction, as indicated by ClinicalTrials.gov. Buprenorphine is a small molecule that acts as a mu opioid receptor agonist, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}